Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the transaction, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Puma Biotechnology Stock Down 5.4 %

PBYI traded down $0.17 during trading on Friday, reaching $2.95. The company had a trading volume of 844,494 shares, compared to its average volume of 763,397. The business’s fifty day moving average price is $2.99 and its 200 day moving average price is $2.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology, Inc. has a 12 month low of $2.22 and a 12 month high of $7.73. The company has a market cap of $144.81 million, a P/E ratio of 6.15 and a beta of 1.08.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the business earned $0.12 EPS. Equities analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Puma Biotechnology during the 3rd quarter worth approximately $34,000. Franklin Resources Inc. bought a new stake in shares of Puma Biotechnology in the third quarter worth $41,000. Dynamic Technology Lab Private Ltd acquired a new position in Puma Biotechnology during the third quarter worth $44,000. Patriot Financial Group Insurance Agency LLC grew its position in Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Royce & Associates LP increased its stake in Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PBYI has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.